Rockwell Medical CEO sells 1,000 shares: what it means for Rockwell Medical stock

Published on 10/06/2026 at 16:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

For Rockwell Medical stock, the filing leaves 61,349 shares held directly. Second-quarter revenue rose 10.60 percent to USD 17.80 million.

RMTI, US7743743004, Illustration mit AI erstellt.

Rockwell Medical (ISIN US7743743004) CEO Mark Strobeck reported the sale of 1,000 shares at USD 8.42 on October 1, 2026, according to StockTitan. The transaction left him with 61,349 shares held directly.

What the sale means for ownership

The filing identified Strobeck as Rockwell Medical's president and chief executive officer. It also stated that the transaction was executed under a Rule 10b5-1 trading plan adopted on May 19, 2026, giving the sale a pre-arranged trading framework rather than presenting it as an open-market decision made without a plan.

The reported sale represented 1,000 shares, while the remaining direct holding was 61,349 shares. The difference between those figures is 60,349 shares, so the disclosed transaction reduced the direct position by 1.63 percent when measured against the 61,349 shares held afterward plus the 1,000 shares sold.

Revenue improves in the second quarter

Rockwell Medical reported USD 17.80 million of revenue in the second quarter of 2026, up 10.60 percent from the same period a year earlier, according to ToAlpha. The same quarterly summary showed a gross margin of 18.20 percent and an operating margin of minus 6.00 percent for that period.

That combination puts the operating result at the center of the stock story: revenue growth was positive, but the operating margin remained negative. Cash flow from operations reached USD 2.08 million in the second quarter of 2026, according to the standardized financial statement data for Rockwell Medical.

Dialysis products remain the core business

Rockwell Medical describes its business as the development, manufacture, commercialization, and distribution of hemodialysis products for dialysis providers worldwide. Its portfolio includes Triferic therapies and dialysis concentrates, placing the company in the specialty healthcare and kidney-disease treatment market.

The company reported cash and cash equivalents of USD 10.52 million on June 30, 2026. Revenue of USD 17.80 million in the second quarter was 2.56 percent higher than the USD 17.34 million reported in the first quarter of 2026, although the operating margin improved only from minus 9.00 percent to minus 6.00 percent.

Nasdaq quote and yearly range

RMTI was last at USD 8.11 on Nasdaq on October 6, 2026 at 10:23 a.m. EDT, while market capitalization stood at USD 32.0 million. The 52-week range was USD 4.89 to USD 12.90 on the same date, leaving the quote USD 4.79 below the yearly high.